StreetInsider.com News Articles

Form 4 Tvardi Therapeutics, For: Jun 09 Filed by: Shah Sujal

Thu, 11 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260611/26636184.html

Form 4 Tvardi Therapeutics, For: Jun 09 Filed by: Shah Sujal

Thu, 11 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260611/26636184.html

Form 4 Tvardi Therapeutics, For: Jun 09 Filed by: HALL WALLACE L JR

Thu, 11 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260611/26636188.html

Form 4 Tvardi Therapeutics, For: Jun 09 Filed by: HALL WALLACE L JR

Thu, 11 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260611/26636188.html

Form 4 Tvardi Therapeutics, For: Jun 09 Filed by: Smith Cynthia

Thu, 11 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260611/26636194.html

Form 4 Tvardi Therapeutics, For: Jun 09 Filed by: Smith Cynthia

Thu, 11 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260611/26636194.html

Form 4 Tvardi Therapeutics, For: Jun 09 Filed by: Shiff Susan Ph.D.

Thu, 11 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260611/26636203.html

Form 4 Tvardi Therapeutics, For: Jun 09 Filed by: Shiff Susan Ph.D.

Thu, 11 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260611/26636203.html

Form 4 Tvardi Therapeutics, For: Jun 09 Filed by: WYZGA MICHAEL S

Thu, 11 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260611/26636177.html

Form 4 Tvardi Therapeutics, For: Jun 09 Filed by: WYZGA MICHAEL S

Thu, 11 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260611/26636177.html

Form 8-K Tvardi Therapeutics, For: Jun 09

Thu, 11 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260611/26635636.html

Form 8-K Tvardi Therapeutics, For: Jun 09

Thu, 11 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260611/26635636.html

H.C. Wainwright Starts Tvardi Therapeutics Inc (TVRD) at Buy

Mon, 08 Jun 2026 06:39:03 -0400

(Updated - June 8, 2026 6:39 AM EDT)

H.C. Wainwright analyst Sara Nik initiates coverage on Tvardi Therapeutics Inc (NASDAQ: TVRD) with a Buy rating and a price target of $9.00.

The analyst comments "An undervalued STAT3 play. We are initiating coverage of Tvardi Therapeutics with a Buy rating and $9 price target. Tvardi is a clinical-stage biopharmaceutical company focused on developing oral, small molecule inhibitors of STAT3, a highly validated but historically undruggable target central to oncogenesis, fibrotic signaling and immune dysregulation. The company’s lead program, TTI-101, is the first direct oral pY-STAT3 inhibitor to enter Phase 2 clinical development and

H.C. Wainwright Starts Tvardi Therapeutics Inc (TVRD) at Buy

Mon, 08 Jun 2026 06:39:03 -0400

(Updated - June 8, 2026 6:39 AM EDT)

H.C. Wainwright analyst Sara Nik initiates coverage on Tvardi Therapeutics Inc (NASDAQ: TVRD) with a Buy rating and a price target of $9.00.

Tvardi Therapeutics to Participate in Upcoming Investor Events

Thu, 21 May 2026 08:00:00 -0400

HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events:

Jefferies Global Healthcare Conference
Format: Fireside Chat and 1-on-1 Meetings
Date: Thursday, June 4, 2026
Time: 8:10 AM ET
Location: New York, NY